• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5080897)   Today's Articles (1074)
For: Yang FF, Hu T, Liu JQ, Yu XQ, Ma LY. Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment. Eur J Med Chem 2023;245:114920. [PMID: 36399875 DOI: 10.1016/j.ejmech.2022.114920] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2022] [Revised: 10/25/2022] [Accepted: 11/08/2022] [Indexed: 11/14/2022]
Number Cited by Other Article(s)
1
Li C, Liu S, Gao J, Xu Y, Peng Q, Weng D, Wang D, Yang W, Yi P, Lin Z, Chen J. Epigenetic activation of PTEN by valproic acid inhibits PI3K/AKT signaling and Burkitt lymphoma cell growth. Gene 2025;950:149369. [PMID: 40021103 DOI: 10.1016/j.gene.2025.149369] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2024] [Revised: 02/11/2025] [Accepted: 02/25/2025] [Indexed: 03/03/2025]
2
Zhang J, Ren X, Song Y, Yu B. JBI-802: the first orally available LSD1/HDAC6 dual inhibitor to enter clinical trials. Expert Opin Ther Pat 2025;35:493-501. [PMID: 39960216 DOI: 10.1080/13543776.2025.2468792] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2024] [Accepted: 02/07/2025] [Indexed: 02/22/2025]
3
He B, Tan HZ, Liu CB, Wu H, He LQ. Synthesis and Antitumor Evaluation of a Novel Class of Chalcone Mannich Base Derivatives. Chem Biol Drug Des 2025;105:e70079. [PMID: 40047275 DOI: 10.1111/cbdd.70079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2024] [Revised: 01/23/2025] [Accepted: 02/18/2025] [Indexed: 03/19/2025]
4
Zou D, Feng S, Hu B, Guo M, Lv Y, Ma R, Du Y, Feng J. Bromodomain proteins as potential therapeutic targets for B-cell non-Hodgkin lymphoma. Cell Biosci 2024;14:143. [PMID: 39580422 PMCID: PMC11585172 DOI: 10.1186/s13578-024-01326-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2024] [Accepted: 11/14/2024] [Indexed: 11/25/2024]  Open
5
Ye F, Huang Y, Zeng L, Li N, Hao L, Yue J, Li S, Deng J, Yu F, Hu X. The genetically predicted causal associations between circulating 3-hydroxybutyrate levels and malignant neoplasms: A pan-cancer Mendelian randomization study. Clin Nutr 2024;43:137-152. [PMID: 39378563 DOI: 10.1016/j.clnu.2024.09.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2024] [Revised: 08/15/2024] [Accepted: 09/26/2024] [Indexed: 10/10/2024]
6
Li X, Wang C, Chai X, Liu X, Qiao K, Fu Y, Jin Y, Jia Q, Zhu F, Zhang Y. Discovery of Potent Selective HDAC6 Inhibitors with 5-Phenyl-1H-indole Fragment: Virtual Screening, Rational Design, and Biological Evaluation. J Chem Inf Model 2024;64:6147-6161. [PMID: 39042494 DOI: 10.1021/acs.jcim.4c01052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/25/2024]
7
Wu Y, Li B, Yu X, Liu Y, Chui R, Sun K, Geng D, Ma L. Histone deacetylase 6 as a novel promising target to treat cardiovascular disease. CANCER INNOVATION 2024;3:e114. [PMID: 38947757 PMCID: PMC11212282 DOI: 10.1002/cai2.114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Revised: 12/31/2023] [Accepted: 01/08/2024] [Indexed: 07/02/2024]
8
Barreca M, Bertoni F, Barraja P. New strategies to hit hematological cancers. Eur J Med Chem 2024;270:116350. [PMID: 38582688 DOI: 10.1016/j.ejmech.2024.116350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/08/2024]
9
Wu C, Song Q, Gao S, Wu S. Targeting HDACs for diffuse large B-cell lymphoma therapy. Sci Rep 2024;14:289. [PMID: 38168914 PMCID: PMC10762105 DOI: 10.1038/s41598-023-50956-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 12/28/2023] [Indexed: 01/05/2024]  Open
10
He B, Ding L, Tan HZ, Liu CB, He LQ. Synthesis and antitumor activity evaluation of coumarin Mannich base derivatives. Chem Biol Drug Des 2024;103:e14389. [PMID: 37955286 DOI: 10.1111/cbdd.14389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Revised: 10/20/2023] [Accepted: 10/23/2023] [Indexed: 11/14/2023]
11
Pan Y, Hou H, Zhou B, Gao J, Gao F. Hydroxamic acid hybrids: Histone deacetylase inhibitors with anticancer therapeutic potency. Eur J Med Chem 2023;262:115879. [PMID: 37875056 DOI: 10.1016/j.ejmech.2023.115879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 10/05/2023] [Accepted: 10/13/2023] [Indexed: 10/26/2023]
12
Ding R, Jiao H, Piao Y, Tian W. Knowledge mapping of immunotherapy for thyroid cancer from 1980 to 2022: A review. Medicine (Baltimore) 2023;102:e35506. [PMID: 37773801 PMCID: PMC10545358 DOI: 10.1097/md.0000000000035506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Accepted: 09/14/2023] [Indexed: 10/01/2023]  Open
13
Jin G, Wang K, Zhao Y, Yuan S, He Z, Zhang J. Targeting histone deacetylases for heart diseases. Bioorg Chem 2023;138:106601. [PMID: 37224740 DOI: 10.1016/j.bioorg.2023.106601] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2023] [Revised: 04/17/2023] [Accepted: 05/05/2023] [Indexed: 05/26/2023]
14
Duan Y, Yu T, Jin L, Zhang S, Shi X, Zhang Y, Zhou N, Xu Y, Lu W, Zhou H, Zhu H, Bai S, Hu K, Guan Y. Discovery of novel, potent, and orally bioavailable HDACs inhibitors with LSD1 inhibitory activity for the treatment of solid tumors. Eur J Med Chem 2023;254:115367. [PMID: 37086699 DOI: 10.1016/j.ejmech.2023.115367] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2022] [Revised: 03/23/2023] [Accepted: 04/09/2023] [Indexed: 04/24/2023]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA